X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: Same bad ideas continue to threaten Part D and beneficiary access to medicines

By Nicole Longo  |    November 13, 2017
Perhaps the biggest fact that is often overlooked about Part D is that there is already significant price negotiation in the program. Thanks to Part D’s competitive structure, large purchasers...   Read More

Video: What is a results-based contract?

By Katie Koziara  |    November 13, 2017
New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies...   Read More

Honoring veterans serving in the biopharmaceutical industry

By Andrew Powaleny  |    November 11, 2017
In honor of Veterans Day, we spoke with Rob Caskey, a senior manager in PhRMA’s finance department about his military service, journey to PhRMA and why veterans make great employees for America’s...   Read More

New report and event examine the new era of vaccines

By Andrew Powaleny  |    November 9, 2017
Today, leading minds will come together for an in-depth conversation centered on vaccines – their critical role in warding off disease, the innovative science powering breakthroughs in their...   Read More

A new era in cancer

By Andrew Powaleny  |    November 1, 2017
The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment. Next week, on Wednesday, November 8, leading minds...   Read More

Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI

By Nicole Longo  |    October 30, 2017
In case you missed it, earlier this month, the Center for Medicare & Medicaid Services formally withdrew a controversial proposal that would have had a detrimental impact on patient access to...   Read More

Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes

By Samantha Dougherty  |    October 24, 2017
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study comparing the effectiveness of oral and...   Read More

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

By Nicole Longo  |    October 20, 2017
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have...   Read More

The Washington Post retracts PhRMA claim in opioid story

By Holly Campbell  |    October 18, 2017
Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its...   Read More

Excerpts from testimony by PhRMA’s Lori Reilly

By Holly Campbell  |    October 17, 2017
Today, Lori Reilly, executive vice president for policy, research and membership at the Pharmaceutical Research and Manufacturers of America (PhRMA), testified at the U.S. Senate Committee on...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates